retatrutide clinical trials safety efficacy Safety, Side Effects & Provider Use Perceived benefits of treatment for
Description
March 28, 2022
Received: 06 January 2026 | Accepted: 12 January 2026 | Published: 20 January 2026 Keywords: GLP-1
Urinary tract infections (UTIs) are one of the most common causes of cloudy urine, leading to more than 8.1 million visits to the doctor every year
Implications: Retatrutide's efficacy surpasses that of single-target GLP-1 agonists, offering a viable option for severe obesity and weight-related comorbidities
Aid in reduction of stress, support sleep and memory
